Hormonal
Pharmacotherapy (specifically topiramate, phentermine, liraglutide, and bupropion/naltrexone) can facilitate weight loss in post-bariatric surgery patients with weight regain or insufficient weight loss, with topiramate showing higher likelihood of significant weight loss compared to other medications.
If lifestyle changes are insufficient, discuss pharmacotherapy with your provider. Topiramate and GLP-1 analogs (like liraglutide) have shown efficacy in helping post-surgery patients lose additional weight. This is often used as an adjunct to behavioral and dietary counseling.
Research found that, among 319 patients with WR or inadequate WL post-RYGB or LSG, 54%, 30.3%, and 15% of the sample lost ≥ 5%, ≥ 10%, and ≥ 15% of their total body weight (TBW) respectively using medications [95]. Furthermore, patients who received topiramate were 1.9 times more likely to lose ≥ 10% of their TBW% compared to those who received other medications [95].
Why this rating
The review notes that studies are often retrospective, small, and lack long-term RCTs, limiting the strength of evidence.
Source
Weight Regain and Insufficient Weight Loss After Bariatric Surgery: Definitions, Prevalence, Mechanisms, Predictors, Prevention and Management Strategies, and Knowledge Gaps—a Scoping Review
Walid El Ansari et al. · Obesity Surgery · 2021
DOI 10.1007/s11695-020-05160-5
More from this paper
- Bariatric surgery (BS) induces initial weight loss through foregut exclusion-mediated hormonal upregulation of satiety hormones (GLP-1, PYY) and downregulation of ghrelin, but long-term weight regain (WR) is driven by the subsequent normalization or decline of these hormonal levels, alongside behavioral factors like dietary non-adherence and grazing.Moderate
- Dietary non-adherence, specifically the consumption of high-calorie liquids, 'grazing' (repeated small meals), and food indiscretion (sweets/fats), is a primary behavioral cause of weight regain and insufficient weight loss after bariatric surgery.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →